Finally, single-cell transcriptomics revealed the complexity of clinical resistance to TKIs (12, 13), suggesting the urgent need to identify specific biomarkers for TKI-resistant blasts in order to develop more effective targeted therapies to treat FLT3-mut AML and prevent relapse (14). This evidence concerns the gene FLT3 and acute myeloid leukemia.